• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nu Holdings, Ally Financial And Some Other Big Stocks Moving Higher In Today's Pre-Market Session

    8/16/22 7:32:58 AM ET
    $ALLY
    $BCAB
    $DNA
    $EMBK
    Major Banks
    Finance
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALLY alert in real time by email
    • Ginkgo Bioworks Holdings, Inc. (NYSE:DNA) shares rose 17.5% to $4.10 in pre-market trading after the company said Q2 sales results were up year over year and raised FY22 sales guidance above estimates.
    • Mainz Biomed B.V. (NASDAQ:MYNZ) rose 16.3% to $10.80 in pre-market trading. Mainz Biomed and Dante Genomics announced full commercial availability of ColoAlert in Italy and the United Arab Emirates.
    • Treasure Global Inc. (NASDAQ:TGL) shares rose 12.8% to $8.12 in pre-market trading after the company reported closing of upsized $9.2 million initial public offering, Nasdaq listing, and full exercise of underwriter’s over-allotment option.
    • Zymergen Inc. (NASDAQ:ZY) gained 12.2% to $3.49 in pre-market trading after declining around 4% on Monday..
    • Nu Holdings Ltd. (NYSE:NU) rose 11.3% to $5.21 in pre-market trading following strong quarterly sales.
    • Magic Empire Global Limited (NASDAQ:MEGL) shares rose 10.1% to $19.52 in pre-market trading. Magic Empire shares jumped over 115% on Monday on volatility following the company's IPO earlier this month.
    • Embark Technology, Inc. (NASDAQ:EMBK) gained 10.1% to $0.8060 in pre-market trading after dipping around 32% on Monday.
    • BioAtla, Inc. (NASDAQ:BCAB) rose 7.1% to $8.57 in pre-market trading.
    • Ternium S.A. (NYSE:TX) gained 6.6% to $37.19 in pre-market trading.
    • Ally Financial Inc. (NYSE:ALLY) shares gained 5.3% to $37.59 in pre-market trading after Berkshire Hathaway boosted its stake in the company.

    Also check this out: Walmart, Home Depot And 3 Stocks To Watch Heading Into Tuesday .

    Get the next $ALLY alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALLY
    $BCAB
    $DNA
    $EMBK

    CompanyDatePrice TargetRatingAnalyst
    Ternium S.A. Ternium S.A.
    $TX
    3/26/2026$40.00Sector Outperform → Sector Perform
    Scotiabank
    Nu Holdings Ltd.
    $NU
    3/19/2026$17.60Neutral → Buy
    UBS
    BioAtla Inc.
    $BCAB
    1/13/2026$4.00Buy
    Rodman & Renshaw
    Ally Financial Inc.
    $ALLY
    1/8/2026$56.00Buy
    UBS
    Ally Financial Inc.
    $ALLY
    1/6/2026$53.00In-line → Outperform
    Evercore ISI
    Ally Financial Inc.
    $ALLY
    12/17/2025$52.00Equal Weight → Overweight
    Wells Fargo
    Ally Financial Inc.
    $ALLY
    10/20/2025$50.00Hold → Buy
    TD Cowen
    Ally Financial Inc.
    $ALLY
    9/2/2025$45.00Underweight → Equal Weight
    Wells Fargo
    More analyst ratings

    $ALLY
    $BCAB
    $DNA
    $EMBK
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Hutchinson Russell E. bought $499,307 worth of shares (11,566 units at $43.17), increasing direct ownership by 5% to 225,336 units (SEC Form 4)

    4 - Ally Financial Inc. (0000040729) (Issuer)

    1/28/26 4:48:14 PM ET
    $ALLY
    Major Banks
    Finance

    Chief Executive Officer Rhodes Michael George bought $991,867 worth of shares (23,800 units at $41.68) (SEC Form 4)

    4 - Ally Financial Inc. (0000040729) (Issuer)

    1/23/26 4:19:05 PM ET
    $ALLY
    Major Banks
    Finance

    Amendment: Large owner Donahue Kevin Michael bought $1,034,350 worth of shares (685,000 units at $1.51) (SEC Form 4)

    4/A - MAINZ BIOMED N.V. (0001874252) (Issuer)

    1/20/26 10:29:36 AM ET
    $MYNZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALLY
    $BCAB
    $DNA
    $EMBK
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    BioAtla Announces Share Consolidation

    SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it will effect a 50-for-1 share consolidation (the "Share Consolidation") of its common stock, par value $0.0001 per share (the "Common Stock"), that is expected to become effective on April 6, 2026 at 12:01 a.m. Eastern Time (the "Effective Date"). The Common Stock will continue to trade on The Nasdaq Capital Market under the existing symbol "BCAB" and is expected to begin trading on a split-adjusted basis when the market opens

    3/31/26 4:06:00 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    Initiated a formal process to monetize assets Implemented a restructuring plan to significantly reduce operating expenses and extend runway SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the full year and fourth quarter ended December 31, 2025 and provided business highlights. "As we evaluate strategic paths forward, our focus remains on supporting the advancement of the ongoing Phase 1 study of BA3182 in adenocarcinomas, while preserving capital, and e

    3/31/26 4:05:00 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ally Financial schedules release of first quarter 2026 financial results

    CHARLOTTE, N.C., March 12, 2026 /PRNewswire/ -- Ally Financial (NYSE:ALLY) has scheduled the release of its first quarter financial results for Friday, April 17, 2026, at approximately 7:30 a.m. ET. The results will be available on the Ally Press Room website (http://media.ally.com). Ally will host a conference call at 9 a.m. ET to review the company's performance. You may listen to the call via webcast or dial-in. The webcast will be live on Ally's Investor Relations website in the Events & Presentations section (http://www.ally.com/about/investor/events-presentations/index.htm

    3/12/26 10:00:00 AM ET
    $ALLY
    Major Banks
    Finance

    $ALLY
    $BCAB
    $DNA
    $EMBK
    SEC Filings

    View All

    Ginkgo Bioworks Holdings Inc. filed SEC Form 8-K: Completion of Acquisition or Disposition of Assets, Financial Statements and Exhibits

    8-K - Ginkgo Bioworks Holdings, Inc. (0001830214) (Filer)

    4/7/26 5:02:07 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    BioAtla Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

    8-K - BioAtla, Inc. (0001826892) (Filer)

    4/2/26 4:05:09 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form S-8 filed by BioAtla Inc.

    S-8 - BioAtla, Inc. (0001826892) (Filer)

    3/31/26 4:50:45 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLY
    $BCAB
    $DNA
    $EMBK
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Junqueira Cristina Helena Zingaretti

    4 - Nu Holdings Ltd. (0001691493) (Issuer)

    3/25/26 8:48:19 PM ET
    $NU
    Finance: Consumer Services
    Finance

    SEC Form 3 filed by new insider Hung Jessica

    3 - Magic Empire Global Ltd (0001881472) (Issuer)

    3/18/26 5:57:08 PM ET
    $MEGL
    Finance: Consumer Services
    Finance

    SEC Form 3 filed by new insider Chen Sze Hon, Johnson

    3 - Magic Empire Global Ltd (0001881472) (Issuer)

    3/18/26 5:55:08 PM ET
    $MEGL
    Finance: Consumer Services
    Finance

    $ALLY
    $BCAB
    $DNA
    $EMBK
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Ternium S.A. downgraded by Scotiabank with a new price target

    Scotiabank downgraded Ternium S.A. from Sector Outperform to Sector Perform and set a new price target of $40.00

    3/26/26 8:42:26 AM ET
    $TX
    Steel/Iron Ore
    Industrials

    Nu Holdings upgraded by UBS with a new price target

    UBS upgraded Nu Holdings from Neutral to Buy and set a new price target of $17.60

    3/19/26 8:23:34 AM ET
    $NU
    Finance: Consumer Services
    Finance

    Rodman & Renshaw initiated coverage on BioAtla with a new price target

    Rodman & Renshaw initiated coverage of BioAtla with a rating of Buy and set a new price target of $4.00

    1/13/26 3:22:40 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLY
    $BCAB
    $DNA
    $EMBK
    Leadership Updates

    Live Leadership Updates

    View All

    Mainz Biomed Announces Appointment of Robert Liscouski as Chairman of the Board of Directors

    BERKELEY, Calif., March 11, 2026 (GLOBE NEWSWIRE) -- Mainz Biomed N.V. (NASDAQ:MYNZ), a molecular genetics diagnostic company specializing in the early detection of cancer, today announced that Robert P. Liscouski has been appointed Chairman of its Board of Directors. Further, the Company announced that it plans to change its name to Quantum Cyber and change its Nasdaq ticker symbol to QUCY, beginning on March 12, 2026. The permanent election of Mr. Liscouski and the change of Company name will become effective at the Company's extraordinary general meeting, being planned for April 2026. The Company will begin doing business as Quantum Cyber and trading under the symbol QUCY beginning on M

    3/11/26 7:30:00 AM ET
    $MYNZ
    $QUBT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Computer Software: Prepackaged Software
    Technology

    Ally Appoints Distinguished Financial Services Executive and Former Regulator Rodney Hood as Senior Policy Advisor to the CEO

    CHARLOTTE, N.C., Jan. 27, 2026 /PRNewswire/ -- Ally Financial Inc. (NYSE:ALLY) today announced the appointment of Rodney Hood as a senior policy advisor to the CEO. In this role, Hood will leverage his nearly three decades of leadership in banking, regulation, risk management and financial inclusion to provide invaluable counsel on political affairs and D.C. engagement, further strengthening Ally's voice in critical policy discussions.  Hood brings an unparalleled depth of experience to Ally, having held multiple presidential appointments across two administrations. He notably

    1/27/26 10:00:00 AM ET
    $ALLY
    Major Banks
    Finance

    Merlin Appoints Ryan Carrithers as Chief Financial Officer, Increasing Public Market Readiness

    Carrithers brings to Merlin a unique blend of technical expertise, capital markets experience, and operational rigor, backed by a proven record in scaling innovative automation and aerospace companies Merlin Labs, Inc., a leading developer of assured, autonomous flight technology for defense customers, today appointed Ryan Carrithers as its new Chief Financial Officer. Carrithers joins Merlin at a pivotal moment as the company prepares to go public in a Business Combination with Inflection Point Acquisition Corp. IV (NASDAQ:BACQ). In this role, he will oversee all of Merlin's financial operations and strategy, investor relations, M&A or strategic partnerships that support its autonomy road

    11/4/25 9:00:00 AM ET
    $ASTR
    $BACQ
    $DNA
    Transportation Services
    Consumer Discretionary
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLY
    $BCAB
    $DNA
    $EMBK
    Financials

    Live finance-specific insights

    View All

    BioAtla Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights

    Initiated a formal process to monetize assets Implemented a restructuring plan to significantly reduce operating expenses and extend runway SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced its financial results for the full year and fourth quarter ended December 31, 2025 and provided business highlights. "As we evaluate strategic paths forward, our focus remains on supporting the advancement of the ongoing Phase 1 study of BA3182 in adenocarcinomas, while preserving capital, and e

    3/31/26 4:05:00 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Ally Financial schedules release of first quarter 2026 financial results

    CHARLOTTE, N.C., March 12, 2026 /PRNewswire/ -- Ally Financial (NYSE:ALLY) has scheduled the release of its first quarter financial results for Friday, April 17, 2026, at approximately 7:30 a.m. ET. The results will be available on the Ally Press Room website (http://media.ally.com). Ally will host a conference call at 9 a.m. ET to review the company's performance. You may listen to the call via webcast or dial-in. The webcast will be live on Ally's Investor Relations website in the Events & Presentations section (http://www.ally.com/about/investor/events-presentations/index.htm

    3/12/26 10:00:00 AM ET
    $ALLY
    Major Banks
    Finance

    Ginkgo Bioworks Reports Fourth Quarter and Full Year 2025 Financial Results, Announces Focus on Autonomous Labs Offerings and Divestiture of its Non-Core Biosecurity Business

    Ginkgo provides an update on its fourth quarter financial resultsBOSTON, Feb. 26, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE:DNA, ", Ginkgo", )) today announced its results for the fourth quarter and full year ended December 31, 2025. The update, including a webcast slide presentation with additional details on the third quarter, as well as supplemental financial information will be available at investors.ginkgobioworks.com. Fourth Quarter 2025 Financial ResultsFourth quarter 2025 Total revenue of $33 million compared to $44 million in the comparable prior year pe

    2/26/26 4:26:00 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ALLY
    $BCAB
    $DNA
    $EMBK
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/14/24 4:31:49 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by BioAtla Inc.

    SC 13G/A - BioAtla, Inc. (0001826892) (Subject)

    11/14/24 4:00:05 PM ET
    $BCAB
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ginkgo Bioworks Holdings Inc.

    SC 13G/A - Ginkgo Bioworks Holdings, Inc. (0001830214) (Subject)

    11/12/24 3:58:52 PM ET
    $DNA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care